BND-35 is an innovative antibody targeting the Ig-like transcript 3 (ILT3) receptor, in development for the treatment of solid tumors known to have a suppressive tumor microenvironment (TME).
BND-35 is planned to enter Phase 1 clinical trials in Q1 2024.
ILT3 is a key protein expressed by suppressive myeloid cells, including tumor-associated macrophages, myeloid-derived suppressive cells and tolerogenic dendritic cells. ILT3 enhances the activity of suppressive myeloid cells and decreases T-cell function, leading to an immuno-suppressive tumor microenvironment, which is known to limit the potency of different therapeutic interventions.
BND-35 has been shown in preclinical studies to restore T cell activity inhibited by different suppressive myeloid cells and to enhance anti-tumor activity in various models. The antibody is in advanced pre-clinical development stages.